PubRank

Lost in transition: A review of the unmet need of patients with attention deficit/hyperactivity disorder transitioning to adulthood.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27552649)

Published in Asia Pac Psychiatry on August 23, 2016

Authors

Tamás Treuer1, Kwok Ling Phyllis Chan2, Bung Nyun Kim3, Ganesh Kunjithapatham4, Dora Wynchank5,6, Bengi Semerci7, William Montgomery8, Diego Novick9, Héctor Dueñas10

Author Affiliations

1: Neuroscience Research, Eli Lilly and Company, Budapest, Hungary.
2: Department of Psychiatry, Queen Mary Hospital, Pokfulam, Hong Kong.
3: Seoul National University Hospital, College of Medicine, Seoul National University, Seoul, South Korea.
4: Institute of Mental Health Singapore, Singapore.
5: PsyQ Expertise Center Adult ADHD, The Hague, The Netherlands.
6: Medical Suite, The Village, Johannesburg, South Africa.
7: Bengi Semerci Institute, Istanbul, Turkey.
8: Global Patient Outcomes & Real World Evidence, Eli Lilly Australia Pty Ltd, West Ryde, New South Wales, Australia.
9: Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Windlesham, Surrey, UK.
10: Eli Lilly de Mexico, Mexico City, Mexico.

Articles by these authors ⇆

Caregiving for patients with Alzheimer's disease or dementia and its association with psychiatric and clinical comorbidities and other health outcomes in Brazil. Int J Geriatr Psychiatry (2015) 0.80

Use of antidepressants in the treatment of depression in Asia: guidelines, clinical evidence, and experience revisited. Asia Pac Psychiatry (2013) 0.78

Predictors of remission in the treatment of major depressive disorder: real-world evidence from a 6-month prospective observational study. Neuropsychiatr Dis Treat (2015) 0.77

Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine. Neuropsychiatr Dis Treat (2015) 0.76

Factors affecting treatment adherence to atomoxetine in ADHD: a systematic review. Neuropsychiatr Dis Treat (2016) 0.75

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia. Neuropsychiatr Dis Treat (2016) 0.75

Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting. Patient Prefer Adherence (2015) 0.75

Recovery in patients with major depressive disorder (MDD): results of a 6-month, multinational, observational study. Patient Prefer Adherence (2017) 0.75